New therapeutic options for musculoskeletal pain

Musculoskeletal pain (MSP) is one of the major interdisciplinary problems of modern medicine and society. Inflammation is a universal mechanism that plays a crucial role in the development of acute and chronic MSP. Therefore, non-steroidal antiinflammatory drugs (NSAIDs) are the first-line treatment for MSP. The effectiveness of all NSAIDs in reducing pain and inflammation is approximately the same, and the degree of safety is determined by their relationship to COX-1 and COX-2 enzymes. Thanks to pharmacological properties and a balanced profile of efficiency and safety, the successful position of the «golden mean» between cokebins and non-selective NSAIDs is a moderately selective aceklofenac, which makes it appropriate for the vast majority of patients with MSP. Introduction into clinical practice of the drug Aceklagin containing 200 mg of aceсlofenaс in a new drug form with modified two-phase release, opens up new possibilities of MSP therapy. Due to the stable concentration of aceclofenac in the body during the day, Aceklagin improves the efficiency of pain and inflammation treatment in patients with MSP, while maintaining a high level of safety inherent in this molecule